Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth ...

OptiNose (OPTN) delivered earnings and revenue surprises of 95.71% and 5.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to ...

OptiNose Inc. OPTN) on Wednesday reported a loss of $360,000 in its fourth quarter.

Reports Q4 revenue $22.418M, consensus $20.82M.Light Up your Portfolio with Spark:Easily identify stocks' risks and opportunities. Discover ...

The average of price targets set by Wall Street analysts indicates a potential upside of 143.1% in OptiNose (OPTN). While the effectiveness of this highly sought-after metric is questionable, the ...

These Stocks Are Moving the Most Today: FedEx, Nike, Micron, Boeing, Super Micro, NIO, Carnival, D-Wave Quantum, and More -- Barrons.com This article is a text version of a Wall Street Journal ...

Lake Street Capital lowered shares of OptiNose (NASDAQ:OPTN – Free Report) from a buy rating to a hold rating in a report issued on Thursday, Marketbeat reports. They currently have $9.00 price ...

Fintel reports that on March 21, 2025, Piper Sandler downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Overweight to ...

Paratek expects the transaction to close "as early as mid-2025". BioPharma currently has a USD71.5 million investment in a USD130 million senior secured loan to OptiNose, which it says would be ...

OptiNose, Inc. (NASDAQ:OPTN) faces a pessimistic outlook from investment analysts with a target price significantly lower than its market price. Collegium Pharmaceutical, Inc. (COLL) is perceived as ...

Fintel reports that on March 20, 2025, Lake Street downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Buy to Hold.